GoldenGolden
University of Texas MD Anderson Cancer Center

University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center is devoted exclusively to cancer patient care, research, education and prevention.

No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.

No article has been written about this topic yet.
Be the first one to add some text.

Loading AI-assisted edit mode...

Timeline

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
April 30, 2021
BioSpace
Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, and Cancer Focus Fund, LP, a unique venture capital fund established in collaboration with The University of Texas MD Anderson Cancer Center ("MD Anderson") to provide funding and clinical expertise to advance promising cancer therapies
BioSpace
April 14, 2021
BioSpace
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules from Boehringer Ingelheim's KRAS (Kirsten rat sarcoma) and TRAILR2 (TNF-related apoptosis-inducing ligand receptor 2) portfolios for the potential treatment of lung cancer, particularly non-small cell lung cancer.
April 8, 2021
BioSpace
TriSalus Life Sciences and MD Anderson Announce Strategic Research Collaboration to Evaluate Treatment of Solid Tumors - read this article along with other careers information, tips and advice on BioSpace
Continental Who's Who
February 16, 2021
www.prnewswire.com:443
/PRNewswire/ -- Asit J. Choksi, MD, FACP, is being recognized by Continental Who's Who as a Leading Oncologist for his outstanding contributions in the field...
Stupid Strong Charitable Foundation
December 23, 2020
www.prnewswire.com:443
/PRNewswire/ -- Stupid Strong Charitable Foundation is proud to contribute $250,000 to The University of Texas MD Anderson Cancer Center to support...
BioSpace
November 18, 2020
BioSpace
Obsidian Therapeutics, Inc. and The University of Texas MD Anderson Cancer Center today announced a multi-year strategic collaboration designed to expedite the research and development of novel engineered tumor infiltrating lymphocytes (TILs) for the treatment of solid tumors.
November 17, 2020
BioSpace
Nanobiotix Announces Two New Phase II Trials Evaluating NBTXR3 in Combination with Anti-PD-1 for the Treatment of Head and Neck Cancer - read this article along with other careers information, tips and advice on BioSpace
BioSpace
November 13, 2020
BioSpace
BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate Navire Pharma, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of its SHP2 inhibitor (BBP-398) in patients with solid tumors driven by mutations in the MAPK signaling pathway, including RAS and receptor tyrosine kinase genes. BBP-398 was developed through a collaboration with The University of Texas MD Anderson Cancer Center's Therapeutics Discovery divis
The University of Texas M. D. Anderson Cancer Center
November 12, 2020
www.prnewswire.com:443
/PRNewswire/ -- The University of Texas MD Anderson Cancer Center has named 10 early-career faculty members to the 2020 class of Andrew Sabin Family Fellows....
November 10, 2020
BioSpace
Immune-Onc Therapeutics Announces Orphan Drug Designation of IO-202 (Anti-LILRB4) for Treatment of AML and Poster Presentation at ASH 2020 - read this article along with other careers information, tips and advice on BioSpace
June 5, 2020
WebWire
The University of Texas MD Anderson Cancer Center and Rakuten Medical, Inc. today announced a strategic alliance collaboration agreement to advance the development of new cancer therapies based on Rakuten Medical's proprietary IlluminoxTM technology platform. Under the terms of the agreement, Rakuten Medical and MD Anderson will collaborate to conduct studies based on the Illuminox technology platform and to determine study designs, combination therapies, and target patient populations f...
June 4, 2020
BioSpace
Rakuten Medical and MD Anderson Announce Strategic Alliance to Advance Illuminox Platform for Cancer Treatments - read this article along with other careers information, tips and advice on BioSpace
BioSpace
May 14, 2020
BioSpace
Helix BioPharma Corp. (TSX: HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that topline data of the recently completed L-DOS47 dose escalation study in combination with pemetrexed and carboplatin in recurrent or metastatic non-squamous non-small cell lung cancer ("LDOS001") will be published at the ASCO 2020 Annual Conference. The A
National Osteoporosis Foundation
May 16, 2019
www.prnewswire.com:443
ARLINGTON, Va., May 16, 2019 /PRNewswire/ -- The National Osteoporosis Foundation (NOF) announces Robert Gagel, MD, Professor of Medicine at MD Anderson Cancer ...
MIHIR ZAVERI
April 22, 2019
www.nytimes.com
The director of the National Institutes of Health said that 55 similar investigations into possible foreign exploitation of American research are happening nationwide.
March 11, 2019
WebWire
New research indicates that colorectal cancer diagnosed at an early age has clinical and genetic features that are different from those seen in traditional colorectal cancer diagnosed later in life. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study also revealed certain unique features in especially young patients and those with predisposing conditions. Although incidence and mortality rates of colorectal cancer have fallen in patients...
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.